Trials / Completed
CompletedNCT01211470
Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus
Randomized, Dose Ranging, Active Controlled Efficacy and Safety Evaluation of PMX-30063 As Initial Treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Staphylococcus Aureus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 215 (actual)
- Sponsor
- PolyMedix, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 84 Years
- Healthy volunteers
- Not accepted
Summary
The study investigates the safety and efficacy of PMX-30063 in patients treated for acute bacterial skin and skin-structure infection (ABSSSI).
Conditions
- Acute Bacterial Skin and Skin-structure Infection(ABSSSI) Due to Staphylococcus Aureus (MSSA)
- (Susceptible or Methicillin Resistant)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Daptomycin | Active Comparator: Daptomycin. |
| DRUG | PMX-30063-investigational drug | Experimental: PMX-30063 |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2011-12-01
- Completion
- 2012-03-01
- First posted
- 2010-09-29
- Last updated
- 2012-05-17
Locations
8 sites across 3 countries: Canada, Russia, Ukraine
Source: ClinicalTrials.gov record NCT01211470. Inclusion in this directory is not an endorsement.